Cencora (COR)
Technical, fundamental, and sentiment analysis with recent related videos.
COR rates Neutral overall. The fundamental read is neutral: the company passes 6 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 4.85); revenue is growing about 10.4% per year; net income is declining about 2.6% per year. The technical picture is neutral: price is 4.3% above the 200-day moving average; 2.4% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is neutral (composite 58/100), based on 6 news articles from recent coverage.
Revenue 3-year avg +10.4%. Net income 3-year avg -2.6%.
Price vs 20DMA +1.3%. RSI 53.34. Bollinger state: Inside Bands.
Composite score 58/100 from the AI judge, based on 6 news items, 0 television segments, and 0 videos.
Latest Market Read
Fundamental is Neutral: revenue has averaged 10.4 percent per year while net income averaged −2.6 percent per year, and the opposing trends leave fundamentals mixed with net income carrying more weight. Technical is Neutral: price sits about 1.3 percent above its 20-day moving average (the average closing price over the last 20 trading days), the Relative Strength Index (RSI), a momentum reading, is 53.3, and the stock trades inside its Bollinger Bands, with a recent Golden cross and MACD support but light volume. Sentiment is Neutral at 58/100, coverage leans constructive around an acquisition but not strong enough to lift the label. All three Neutral badges produce an Overall Neutral rating.
Recent news: Coverage is mixed: bullish items highlight Cencora's acquisition of American Oncology Network, which adds a physician-led network of 350+ oncology providers across 21 states and an updated 2026 outlook citing potential revenue upside and cost synergies, and an institutional buyer purchased about $2.334M of stock in Q3; however, analysts showed mixed reactions with UBS trimming its price target and the company flagged integration risks tied to the deal. Overall sources agree the acquisition is strategically accretive but caution that near-term guidance changes and execution risk temper immediate upside.
Latest Videos
- No qualified videos yet.